US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Vaccinex, Inc. - Common Stock (NQ:VCNX)

1.410 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaccinex, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
This first-in-class differentiated approach will be highlighted during a Featured Research Session entitled Alzheimer's therapy: mechanisms beyond amyloid 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports 2025 Annual Financial Results
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024 ↗
Vaccinex just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock? ↗
Vaccinex, Inc. (NASDAQ: VCNX) shares are trading lower after the company announced it received a delisting notification from Nasdaq. Here's what you need to know. 
Via Benzinga
News headline image
Crude Oil Down Over 1%; US Industrial Production Declines In November ↗
 
Via Benzinga
News headline image
Dow Dips Over 200 Points; US Retail Sales Top Estimates ↗
 
Via Benzinga
Topics Stocks
News headline image
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Partnerships will employ Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s disease 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
In addition to cognitive benefit, pepinemab is believed to preserve vascular integrity in brain, a key consideration to avoid toxicity in Alzheimer’s disease 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
What's Going On With Vaccinex Stock Wednesday? ↗
Vaccinex shares are trading lower on Wednesday after the company announced $6.2 million in proceeds from the exercise of warrants as well as the issuance of new warrants for common stock. 
Via Benzinga
News headline image
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s disease 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying ↗
 
Via Benzinga
News headline image
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
It's time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
News headline image
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning! 
Via InvestorPlace
News headline image
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progression 
From Vaccinex, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >